BiotechNow what? How biotechs deal with failure By Robert Weisman — Boston GlobeJuly 12, 2016 Reprints Aveo Pharmaceuticals is pressing forward three years after US regulators rejected its kidney cancer drug candidate and three months after a trio of former executives were charged with fraud. Suzanne Kreiter/Boston Globe Now what? How biotechs deal with failure About the Author Reprints Robert Weisman — Boston Globe [email protected] @GlobeRobW
Special Report Lizzy Lawrence STAT Plus: Lured by a bigger payday, a medical device maker sold fake plastic parts. Many were implanted in chronic pain patients
Exclusive Rachel Cohrs STAT Plus: With Fat Joe concerts and Super Bowl ads, a cadre of billionaires is mounting an unorthodox campaign against hospitals
Matt's Take Matthew Herper STAT Plus: Battle for the soul of Illumina is also a referendum on its CEO
Biotech Allison DeAngelis STAT Plus: Biotech launches with $300 million, joint venture to expedite RNA drug development
Health Tech Casey Ross, Brittany Trang and Mario Aguilar STAT Plus: What does generative AI mean for health care? We asked the experts
